Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Derwent London plc REIT ( (GB:DLN) ) has provided an announcement.
Derwent London plc has confirmed that, as of 30 January 2026, its issued share capital comprises 112,290,929 ordinary shares of 5 pence each, all of which carry voting rights, with no shares held in treasury. This disclosure sets the official total of voting rights at 112,290,929, providing shareholders and market participants with the denominator needed to assess whether they must notify the Financial Conduct Authority of any holdings or changes in holdings under the UK’s Disclosure and Transparency Rules, thereby supporting ongoing transparency in the company’s shareholder base and regulatory compliance.
The most recent analyst rating on (GB:DLN) stock is a Hold with a £2078.00 price target. To see the full list of analyst forecasts on Derwent London plc REIT stock, see the GB:DLN Stock Forecast page.
Spark’s Take on GB:DLN Stock
According to Spark, TipRanks’ AI Analyst, GB:DLN is a Outperform.
Derwent London plc’s strong valuation and positive corporate events are the primary drivers of its score. Despite a bearish technical outlook, the company’s financial stability and strategic initiatives in the real estate market support a cautiously optimistic view.
To see Spark’s full report on GB:DLN stock, click here.
More about Derwent London plc REIT
Derwent London plc is a UK-listed real estate investment trust (REIT) focused on owning, developing and managing commercial property, primarily in central London. The company’s portfolio typically consists of office-led mixed-use buildings, positioning it as a significant player in the capital’s prime workspace and urban regeneration market.
Average Trading Volume: 276,448
Technical Sentiment Signal: Hold
Current Market Cap: £2.19B
See more insights into DLN stock on TipRanks’ Stock Analysis page.

